Category: Blood Flow

Description

This page contains brief details about the drug ranibizumab, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Ranibizumab is an anti-neovascularisation agent in the class of medications called vascular endothelial growth factor A (VEGF-A) antagonists. Initially, FDA approved this medicine on 30th June 2006 for its medical use.

Mechanism of Action of Ranibizumab

Ranibizumab specifically recognizes and binds to a protein called human vascular endothelial growth factor A (VEGF-A) present in the eye. In excess, VEGF-A causes abnormal blood vessel growth and swelling in the eye, leading to impairment of vision in certain eye diseases. This medicine can block its actions and prevent this abnormal growth and swelling. This injection can help to stabilize and improve your vision.

Uses of Ranibizumab

It is used in adults to treat several eye diseases causing vision impairment. It is used to treat wet age-related macular degeneration (AMD, a persistent eye disease that causes loss of the ability to see straight ahead and may make it more difficult to read, drive, or perform other daily activities).

Ranibizumab is also used to treat myopic choroidal neovascularization (mCNV; a complication in near-sighted people where new blood vessels can grow in the back of the eye), and to treat macular edema after retinal vein occlusion (an eye disease caused by blockage of blood flow from the eye that leads to blurry vision and vision loss). It is also used to treat diabetic macular edema (an eye disease caused by diabetes that can lead to vision loss) and diabetic retinopathy (damage to the eyes caused by diabetes).

Ranibizumab Dosage available Ranibizumab is administered as an injection into your eye by an eye doctor under a local anesthetic. Your doctor will decide the dose and frequency of the injection based on your disease condition. Do not self-administer the medicine.